234 related articles for article (PubMed ID: 28521697)
1. An Accelerated Release Method of Risperidone Loaded PLGA Microspheres with Good IVIVC.
Hu X; Zhang J; Tang X; Li M; Ma S; Liu C; Gao Y; Zhang Y; Liu Y; Yu F; Yang Y; Guo J; Li Z; Mei X
Curr Drug Deliv; 2018; 15(1):87-96. PubMed ID: 28521697
[TBL] [Abstract][Full Text] [Related]
2. In vitro-in vivo correlation of parenteral risperidone polymeric microspheres.
Shen J; Choi S; Qu W; Wang Y; Burgess DJ
J Control Release; 2015 Nov; 218():2-12. PubMed ID: 26423236
[TBL] [Abstract][Full Text] [Related]
3. Development of andrographolide loaded PLGA microspheres: optimization, characterization and in vitro-in vivo correlation.
Jiang Y; Wang F; Xu H; Liu H; Meng Q; Liu W
Int J Pharm; 2014 Nov; 475(1-2):475-84. PubMed ID: 25219858
[TBL] [Abstract][Full Text] [Related]
4. Sustained release of risperidone from biodegradable microspheres prepared by in-situ suspension-evaporation process.
An T; Choi J; Kim A; Lee JH; Nam Y; Park J; Sun Bk; Suh H; Kim CJ; Hwang SJ
Int J Pharm; 2016 Apr; 503(1-2):8-15. PubMed ID: 26899975
[TBL] [Abstract][Full Text] [Related]
5. Microsphere delivery of Risperidone as an alternative to combination therapy.
D'Souza S; Faraj J; DeLuca P
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):631-9. PubMed ID: 23892159
[TBL] [Abstract][Full Text] [Related]
6. A novel accelerated in vitro release method to evaluate the release of thymopentin from PLGA microspheres.
Xie X; Li Z; Zhang L; Chi Q; Yang Y; Zhang H; Yang Y; Mei X
Pharm Dev Technol; 2015; 20(5):633-40. PubMed ID: 24597702
[TBL] [Abstract][Full Text] [Related]
7. In vitro-in vivo correlation of PLGA microspheres: Effect of polymer source variation and temperature.
Wan B; Bao Q; Burgess DJ
J Control Release; 2022 Jul; 347():347-355. PubMed ID: 35569590
[TBL] [Abstract][Full Text] [Related]
8. Characterizing release mechanisms of leuprolide acetate-loaded PLGA microspheres for IVIVC development I: In vitro evaluation.
Hirota K; Doty AC; Ackermann R; Zhou J; Olsen KF; Feng MR; Wang Y; Choi S; Qu W; Schwendeman AS; Schwendeman SP
J Control Release; 2016 Dec; 244(Pt B):302-313. PubMed ID: 27565212
[TBL] [Abstract][Full Text] [Related]
9. A reproducible accelerated in vitro release testing method for PLGA microspheres.
Shen J; Lee K; Choi S; Qu W; Wang Y; Burgess DJ
Int J Pharm; 2016 Feb; 498(1-2):274-82. PubMed ID: 26705156
[TBL] [Abstract][Full Text] [Related]
10. Effects of formulation parameters on encapsulation efficiency and release behavior of risperidone poly(D,L-lactide-co-glycolide) microsphere.
Su Z; Sun F; Shi Y; Jiang C; Meng Q; Teng L; Li Y
Chem Pharm Bull (Tokyo); 2009 Nov; 57(11):1251-6. PubMed ID: 19881277
[TBL] [Abstract][Full Text] [Related]
11. [Preparation and evaluation of risperidone-loaded microsphere/sucrose acetate isobutyrate in situ forming complex depot with double diffusion barriers].
Lin X; Tang X; Xu YH; Zhang Y; Zhang Y; He HB
Yao Xue Xue Bao; 2015 Jun; 50(6):775-82. PubMed ID: 26521452
[TBL] [Abstract][Full Text] [Related]
12. Beyond Q1/Q2: The Impact of Manufacturing Conditions and Test Methods on Drug Release From PLGA-Based Microparticle Depot Formulations.
Garner J; Skidmore S; Park H; Park K; Choi S; Wang Y
J Pharm Sci; 2018 Jan; 107(1):353-361. PubMed ID: 29107048
[TBL] [Abstract][Full Text] [Related]
13. Comparison of in vitro-in vivo release of Risperdal(®) Consta(®) microspheres.
Rawat A; Bhardwaj U; Burgess DJ
Int J Pharm; 2012 Sep; 434(1-2):115-21. PubMed ID: 22659126
[TBL] [Abstract][Full Text] [Related]
14. Accelerated in vitro release testing method for naltrexone loaded PLGA microspheres.
Andhariya JV; Choi S; Wang Y; Zou Y; Burgess DJ; Shen J
Int J Pharm; 2017 Mar; 520(1-2):79-85. PubMed ID: 28153651
[TBL] [Abstract][Full Text] [Related]
15. IVIVC of parenteral PLGA microspheres.
Park K
J Control Release; 2015 Nov; 218():116. PubMed ID: 26526216
[No Abstract] [Full Text] [Related]
16. Development of in vitro-in vivo correlation of parenteral naltrexone loaded polymeric microspheres.
Andhariya JV; Shen J; Choi S; Wang Y; Zou Y; Burgess DJ
J Control Release; 2017 Jun; 255():27-35. PubMed ID: 28385676
[TBL] [Abstract][Full Text] [Related]
17. Effect of bases with different solubility on the release behavior of risperidone loaded PLGA microspheres.
Hu Z; Liu Y; Yuan W; Wu F; Su J; Jin T
Colloids Surf B Biointerfaces; 2011 Aug; 86(1):206-11. PubMed ID: 21524893
[TBL] [Abstract][Full Text] [Related]
18. 3-month parenteral PLGA microsphere formulations of risperidone: Fabrication, characterization and neuropharmacological assessments.
Chaurasia S; Mounika K; Bakshi V; Prasad V
Mater Sci Eng C Mater Biol Appl; 2017 Jun; 75():1496-1505. PubMed ID: 28415443
[TBL] [Abstract][Full Text] [Related]
19. Biodegradable poly(D, L-lactide-co-glycolide) (PLGA) microspheres for sustained release of risperidone: Zero-order release formulation.
Su ZX; Shi YN; Teng LS; Li X; Wang LX; Meng QF; Teng LR; Li YX
Pharm Dev Technol; 2011 Aug; 16(4):377-84. PubMed ID: 20370594
[TBL] [Abstract][Full Text] [Related]
20. In Vitro-In Vivo Relationship of Amorphous Insoluble API (Progesterone) in PLGA Microspheres.
Pu C; Wang Q; Zhang H; Gou J; Guo Y; Tan X; Xie B; Yin N; He H; Zhang Y; Wang Y; Yin T; Tang X
Pharm Res; 2017 Dec; 34(12):2787-2797. PubMed ID: 28948463
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
